Journal article icon

Journal article

P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.

Abstract:

BACKGROUND: Although remarkable clinical response rates in melanoma have been observed using vemurafenib or dabrafenib in patients with tumors carrying oncogenic mutations in BRAF, a substantial unmet medical need remains for the subset of patients with wild-type BRAF tumors. METHODS: To investigate the role of p21-activated kinases (PAKs) in melanoma, we determined PAK1 genomic copy number and protein expression for a panel of human melanoma tissues. PAK1 was inhibited in vitro and in vivo u...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1093/jnci/djt054

Authors


Jakubiak, D More by this author
Rudolph, J More by this author
Expand authors...
Journal:
Journal of the National Cancer Institute
Volume:
105
Issue:
9
Pages:
606-607
Publication date:
2013-05-05
DOI:
EISSN:
1460-2105
ISSN:
0027-8874
URN:
uuid:51e1ef07-bd18-4091-a9a9-48f9adb0077b
Source identifiers:
390881
Local pid:
pubs:390881

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP